EFORT Annual Congress

EFORT Annual Congress

Source:

Graves SE, et al. Paper 964. Presented at: Virtual EFORT Congress; June 30 – July 2, 2021.

Disclosures: Duszynski reports no relevant financial disclosures.
July 07, 2021
1 min read
Save

Rivaroxaban reduced mortality risk, reoperation rates after THA, TKA

Source:

Graves SE, et al. Paper 964. Presented at: Virtual EFORT Congress; June 30 – July 2, 2021.

Disclosures: Duszynski reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Results showed use of rivaroxaban after total hip or knee arthroplasty led to lower mortality risk and decreased reoperation rates due to infection or hematomas compared with low-molecular-weight heparin.

Katherine Duszynski and colleagues used data from the Australian National Joint Replacement Registry linked with medicines dispensing and medical services data to identify new anticoagulant use 35 days after unilateral primary total hip or total knee replacement, 90-day mortality and a composite outcome of revision surgery for infection or hematoma aspiration.

“We calculated the proportion of procedures with new anticoagulant dispensing following surgery, used Cox proportional hazard models to model time to death with the reference medication being low-molecular-weight heparin and multivariate Fine and Gray models to estimate the association between anticoagulant products and 90-day risk of reoperation for infection or hematoma,” Duszynski said in her presentation at the Virtual EFORT Congress.

Katherine Duszynski
Katherine Duszynski

Duszynski noted 70% of patients undergoing THA or TKA received an anticoagulant in the first 35 days following surgery, with a decrease in the use of injectable anticoagulants, predominantly low-molecular-weight heparin, and an increase in the use of oral anticoagulants, predominantly rivaroxaban. She added they found a low use of apixaban among patients.

Results showed no significant differences in mortality risk among patients undergoing THA who received either rivaroxaban or aspirin. Patients undergoing TKA who received rivaroxaban had a significantly reduced risk of mortality compared with patients who received low-molecular-weight heparin, according to Duszynski.

“When compared to low-molecular-weight heparin, a decreased risk of reoperation for infection or hematoma were seen for hip patients dispensed rivaroxaban and for knee patients dispensed rivaroxaban or apixaban,” Duszynski said.